AstraZeneca Plc’s previously-announced plans to build its oncology portfolio has taken shape with the announcement of three projects: a review of technology to monitor tumour activity and work on therapies for prostate and pancreatic cancers. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
